The InSite™ Her-2/neu kit from BioGenex Laboratories Inc is used to identify breast cancer patients eligible for treatment with the cancer drug Herceptin®. InSite Her-2/neu is a complete kit, in manual and automated format, that contains all components required for the performance of immunohistochemistry staining of breast cancer tissue. The test detects Her-2/neu tyrosine kinase protein in the body that stimulates cancerous cell growth. The detection of this protein indicates eligibility for breast cancer treatment with Herceptin.
     The kit’s automated format is designed for use on the BioGenex i6000™ automated staining system and the OptiMax® Plus consolidated staining system. The company offers more than 250 IHC tests for cancer diagnosis, prognosis, and therapy selection, including a complete panel for breast cancer with additional FDA-cleared tests.

BioGenex Laboratories Inc
(800) 421-4129; www.biogenex.com